MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
about
The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy'Micro-managers' of hepatic lipid metabolism and NAFLDThe effects of microRNA on the absorption, distribution, metabolism and excretion of drugsMiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 CellsCarboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot StudyMicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.miR-185 enhances the inhibition of proliferation and migration induced by ionizing radiation in melanoma.Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis.MicroRNA-152 regulates DNA methyltransferase 1 and is involved in the development and lactation of mammary glands in dairy cowsMicroRNAs: novel players in cancer diagnosis and therapies.MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2MicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells.miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro.Clinically relevant microRNAs in ovarian cancerMetformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma.Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer.The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagyChromosomal Integrity after UV Irradiation Requires FANCD2-Mediated Repair of Double Strand Breaks.Beyond genomics: critical evaluation of cell line utility for ovarian cancer researchmiR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer CellsMiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells.TGF-β induces HLA-G expression through inhibiting miR-152 in gastric cancer cells.Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human CancersHistone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer DrugsmiR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes.Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry-based imagingIdentification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinomaMicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain.Oncogenes associated with drug resistance in ovarian cancer.Restoring TRAIL mediated signaling in ovarian cancer cells.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.miRNA and methylation: a multifaceted liaison.miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.
P2860
Q26778301-75FBE72D-97CB-402B-91D6-202F55CB813DQ26801228-34B3C6BE-9EFD-4E90-942A-E5E9812CD491Q26822987-C34D6352-1945-4E08-9FAE-E966829426B6Q28547840-5027A09A-09DE-4D04-A921-5F6FA2E7321BQ28550381-4FA5341E-63AC-4D9E-8A22-B5734D7CF75CQ30244282-5B016551-DA42-44EE-A282-223EF5AB1465Q33597730-52DA85ED-E606-4378-95B6-725B98A3EF5AQ33641799-C3594CC0-B749-4C7B-A8F3-61F0DDA4EA1AQ33837871-44E7D08D-B195-4C09-A627-A8892EAF3CBAQ33914573-D037CEB8-071D-493B-B3D9-AB7CF39AE653Q34116259-FEB7DC10-0866-4445-A953-A06398328688Q34444017-CF50E6A4-4574-42EE-9939-5583E8BB5CC1Q35051983-B932B8D8-DE9E-44F6-B7FC-519467393C20Q35204609-734B2704-48D7-442B-9BF2-D53E658DED82Q35550204-D240F616-C9ED-45A5-9FCB-2AA6FA76127EQ35666478-2E9FA4AB-36C4-4873-9F37-1D78955B64E6Q35666862-703AEAEC-375C-407A-B543-C651F85437C4Q35741623-A79B6033-2C75-4CF4-A021-DC5DD89EB354Q35799311-14FE203E-2193-48C0-9B1A-2D9F6DB696B5Q35852880-315843CA-C130-49E1-BABE-D2106EE3A0D3Q35893816-4EFC27F5-0EEC-45C9-8BD5-007EE3589DF6Q36104020-177EAD32-A474-4A9D-AA57-C826E0A8A1A6Q36145468-59FEB750-92E2-4989-B30A-4B43DE203FB5Q36240460-25B66E9D-0ABE-4D40-BE4C-57C4AEE94450Q36262119-C0A79859-1445-44BA-8DB0-E3C0AA2F5793Q36340968-7FBBD084-B324-4607-9A97-8B0F9A010177Q36494718-A372D48D-21F3-4CEB-A213-EACCED216086Q36657311-98D69FEE-E67A-4B26-8B97-AC6BE9FC8842Q36693836-9706D7E7-3788-4561-A52B-4DD90E9AE114Q36782334-1422A75D-B565-46F3-A543-B0812F304C82Q36820568-63B09532-4C6D-455B-890E-D026E91F0A43Q36846957-4F28CA0D-7230-4438-A70D-3C2320129C39Q37256221-E19B89C0-2C5E-4D0F-B40B-E5E186F00748Q37295826-8913D84A-3D0A-464F-8D93-F215EE0DC116Q37726121-FBAF0166-8EA8-4565-B43C-461B19D9E60CQ38226577-FDADE6F0-D8AB-47AF-B039-C5365A89F9BBQ38230205-2941CC8B-1799-4150-A643-450BAB2CE8B1Q38258014-75348893-4079-4B40-A4AE-14728C5E23E4Q38282163-1714BDC1-C826-4359-B0DD-E66DC6A3BEB0Q38366731-F41F132B-1368-4EA8-B0B0-A8B77F6C7C36
P2860
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@en
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@nl
type
label
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@en
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@nl
prefLabel
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@en
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@nl
P2093
P2860
P356
P1433
P1476
MiR-152 and miR-185 co-contrib ...... apy independent of decitabine.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.575
P407
P577
2013-01-14T00:00:00Z
P5875
P6179
1037543600